Publications by authors named "Stephen William Fenwick"
Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Jonathan S Zager Marlana Orloff Pier Francesco Ferrucci Junsung Choi David J Eschelman Stephen William Fenwick
Ann Surg Oncol
November 2024
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Jonathan S Zager Marlana Orloff Pier Francesco Ferrucci Junsung Choi David J Eschelman Stephen William Fenwick
Ann Surg Oncol
August 2024
Article Synopsis
- Uveal melanoma (UM) often leads to poor outcomes once it spreads to the liver, and the FOCUS study evaluated the effectiveness and safety of a treatment combining melphalan with a delivery system (melphalan/HDS) for patients with unresectable metastatic UM.
- In the study, 102 patients were enrolled, with 91 receiving treatment; the objective response rate (ORR) was 36.3%, and the median duration of response was 14 months.
- The findings suggest melphalan/HDS is effective, showing a median overall survival of 20.5 months and a good safety profile, with no treatment-related deaths reported.